Esomeprazole agnesium trihydrate

Research use only, not for human use.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells; the (S)-( )-enantiomer of omeprazole for treatment of dyspepsia, peptic ulcer disease, and gastroesophageal reflux disease.Ulcer Approved(In Vitro):Esomeprazole magnesium trihydrate is develped from Esomeprazole strontium tetrahydrate (EST). EST contains esomeprazole, the S-enantiomer of omeprazole a salt-exchanged version of Esomeprazole magnesium trihydrate.(In Vivo):Esomeprazole magnesium (0.5-50 mg/kg; oral gavage; daily; for 10 days; A/J mice) treatment increases gastric total antioxidant capacity and Cu/Zn-superoxide dismutase activity.

Esomeprazole magnesium trihydrate is develped from Esomeprazole strontium tetrahydrate (EST). EST contains esomeprazole, the S-enantiomer of omeprazole a salt-exchanged version of Esomeprazole magnesium trihydrate.

Esomeprazole magnesium (0.5-50 mg/kg; oral gavage; daily; for 10 days; A/J mice) treatment increases gastric total antioxidant capacity and Cu/Zn-superoxide dismutase activity. Animal Model:A/J mice Dosage:0.5 mg/kg, 5 mg/kg, 50 mg/kg Administration:Oral gavage; daily; for 10 days Result:Gastric total antioxidant capacity and Cu/Zn-superoxide dismutase activity are increased.

S)-Omeprazole magnesium trihydrate

Membrane Transporter/Ion Channel

Proton Pump

Proton Pump

Other Indications

Ulcer

217087-09-7

767.1671

C34H42MgN6O9S2

>98% (HPLC)

10 mM in DMSO

[H]O[H].[H]O[H].[H]O[H].O=S(CC1=NC=C(C)C(OC)=C1C)C2=NC(C=CC(OC)=C3)=C3[N-]2.O=S(CC4=NC=C(C)C(OC)=C4C)C5=NC(C=CC(OC)=C6)=C6[N-]5.[Mg+2]

Magnesium, bis[6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-κO]-1H-benzimidazolato-κN3]-, hydrate (1:3), (T-4)-

(-20℃)

With Ice Pack

≥ 2 years